Abstract
Almost all antibiotics are known to appear in saliva and bronchial secretions, at least in trace amounts. However, in these secretions certain antibiotics reach concentrations equivalent to or even higher than the M.I.C. for numerous bacterial strains or genera that are responsible for the most common respiratory disorders. Such pharmacokinetic data are therefore of great interest for the choice of the most suitable antibiotic therapy for a bacterial infection of the respiratory system. The exact mechanism underlying penetration of antibiotics into the lung, of their secretion into saliva, or at least all of the factors involved, are still unknown [1]. Antibiotics reach the bronchopulmonary system and saliva in two completely different ways. Salivary secretion is related to pharmacokinetic processes and to the degree of tropism for tissues, because the salivary glands do not offer any appreciable barrier to antibiotic penetration. On the contrary, the concentration of antibiotics in the respiratory system seems to be completely independent of serum levels, and in healthy subjects bronchopulmonary concentrations are usually much lower (30–40 times) than those in the serum. These pharmacokinetic data led to the conclusion that there must be a blood-lung, or rather a blood-bronchi, barrier that may be even less permeable than the better-known blood-brain barrier [2]. However, certain antibiotics reach surprisingly high (macrolides, lincomycin, rifampin, chloramphenicol) or at least therapeutic (ampicillin, cefalosporins) levels in the bronchi. This phenomenon has led some authors to suggest the existence of a mechanism of active transport able to concentrate some antibiotics selectively in bronchial mucus [3,4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Matsumoto K, Uzuka Y: Concentrations of antibiotics in bronchiolar secretions of the patients with chronic respiratory infections. In: Chemotherapy (Williams JD, Geddes AM, eds.), Plenum Press, New York, Plenum Press, 1975, 4, p. 73.
Fraschini F, Copponi V, Dubini F, Scarpazza G: Concentration of erythromycin and ampicillin in bronchial secretions of patients with chronic respiratory infections. In: Current Chemotherapy (Siegenthaler W, Lüthy R (eds.), American Society for Microbiology Washington DC, 1978, p. 650.
May JR, Delves DM: Treatment of chronic bronchitis with ampicillin: some pharmacological observations. Lancet i: 929, 1965.
Saggers BA, Lawson D: In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Childh 43: 404, 1968.
Saggers BA, Lawson D: Some observations on the penetration of antibiotics through mucus in vitro. J Clin Path 19: 313, 1966.
Simon C and Clasen I: Sputum concentrations of erythromycin after single and repeated oral administration in adult patients with bronchitis. In: Current Chemotherapy ( Siegenthaler W, Lüthy R. (eds.), American Society for Microbiology. Washington DC, 1978, p. 652.
Dubini F, Faraone P, Guastamacchia C, Fraschini F: Riccrca della eritromicina e della spiramicina nella saliva. Dental Cadmos 10: 1, 1976.
Sheila M, Stewart Fisher M, Young JE, Lutz W: Ampicillin levels in sputum, serum and saliva. Thorax 25: 304, 1970.
Fraschini F, Braga PC, Copponi V, Scaglione F, Fumagalli G, Gattei G, Scarpazza G: Penetration of erythromycin into the bronchi. Acta Pediatrica Belgica, 1980, in press.
Balbirsingh M, Dorn J, Klainer AS, Liss RH, Norman JC, Ward EE: Erythromyrin. In: Current chemotherapy ( Siegenthaler W, Lüthy R, (eds.), American Society for Microbiology. Washington DC, 1978, p. 650.
Gould JC: Personal communication.
Dette G: Personal communication.
Canad Med Asso J.: Concentration of orally administered erythromycin and tetracycline in ischemic tissue. Med News in Brief 85: 504, 1961.
Fraschini F, Braga PC, Copponi V, Gattei G, Guerrasio E, Scaglione F, Villa F, Scarpazza G: Tropism of erythromycin for respiratory system. Communication. In: Current Chemotherapy and Infections Disease. ( Nelson JD, Grassi C, eds.), American Society for Microbiology, Washington DC, 1980, p. 659.
Fraschini F, Avallon R, Copponi V, Fumagalli G, Mandler F, Scaglione F, Scarpazza G: Bactericidal action of an average dose of erythromycin in the bronchi. Current Med Res Opinion 6: 107, 1979.
Stephens VC, Puch CT, Davis NE, Hoehn MM, Ralston S, Sparks MC, Thompkins L.: A study of the behavior of propionyl erythromycin in blood by a new chromatographic method. J Antibiot 22: 551, 1969.
Neaverson MA: Intravenous administration of erythromycin: serum, sputum, and urine levels. Curr Med Res Opinion 4: 359, 1976.
MacFarlane, JA, Mitchell AA B, Walsh JM, Robertson J: Spiramycin in the prevention of postoperative staphylococcal infection. Lancet i: 1, 1969.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Martinus Nijhoff Publishers, The Hague
About this chapter
Cite this chapter
Fraschini, F., Falchi, M., Copponi, V. (1981). Penetration of Macrolides into the Respiratory Tract. In: Van Furth, R. (eds) Developments in Antibiotic Treatment of Respiratory Infections. New Perspectives in Clinical Microbiology, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8305-2_7
Download citation
DOI: https://doi.org/10.1007/978-94-009-8305-2_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8307-6
Online ISBN: 978-94-009-8305-2
eBook Packages: Springer Book Archive